XML 16 R5.htm IDEA: XBRL DOCUMENT v3.25.2
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($)
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated other Comprehensive Income (Loss)
Total
Balance at Dec. 31, 2023 $ 435 $ 61,732,106 $ (52,221,741) $ 27,260 $ 9,538,060
Balance (in Shares) at Dec. 31, 2023 4,348,129        
Exercise of pre-funded warrants $ 5 (5)
Exercise of pre-funded warrants (in Shares) 55,675        
Stock-based compensation 513,350 513,350
Deferred offering cost related to warrant inducement 550,500 550,500
Cumulative translation adjustment (5,768) (5,768)
Net loss (2,146,529) (2,146,529)
Balance at Mar. 31, 2024 $ 440 62,795,951 (54,368,270) 21,492 8,449,613
Balance (in Shares) at Mar. 31, 2024 4,403,804        
Balance at Dec. 31, 2023 $ 435 61,732,106 (52,221,741) 27,260 9,538,060
Balance (in Shares) at Dec. 31, 2023 4,348,129        
Net loss         (3,856,693)
Balance at Jun. 30, 2024 $ 536 65,934,709 (56,078,434) 23,126 9,879,937
Balance (in Shares) at Jun. 30, 2024 5,358,804        
Balance at Mar. 31, 2024 $ 440 62,795,951 (54,368,270) 21,492 8,449,613
Balance (in Shares) at Mar. 31, 2024 4,403,804        
Stock-based compensation 7,054 7,054
Common shares issued and issuable for exercise of warrants (1) [1] $ 96 3,682,204 3,682,300
Common shares issued and issuable for exercise of warrants (1) (in Shares) [1] 955,000        
Deferred offering cost related to warrant inducement (550,500) (550,500)
Cumulative translation adjustment 1,634 1,634
Net loss (1,710,164) (1,710,164)
Balance at Jun. 30, 2024 $ 536 65,934,709 (56,078,434) 23,126 9,879,937
Balance (in Shares) at Jun. 30, 2024 5,358,804        
Balance at Dec. 31, 2024 $ 804 67,279,033 (60,410,041) 9,063 $ 6,878,859
Balance (in Shares) at Dec. 31, 2024 8,042,747       8,042,747
Common shares issued for exercise of warrants $ 375 5,624,625 $ 5,625,000
Common shares issued for exercise of warrants (in Shares) 3,750,000        
Stock-based compensation 219,929 219,929
Common stock issued for cash, net $ 93 1,441,871 1,441,964
Common stock issued for cash, net (in Shares) 927,968        
Common stock issued for patent $ 45 850,455 850,500
Common stock issued for patent (in Shares) 450,000        
Cumulative translation adjustment (497) (497)
Net loss (3,475,836) (3,475,836)
Balance at Mar. 31, 2025 $ 1,317 75,415,913 (63,885,877) 8,566 11,539,919
Balance (in Shares) at Mar. 31, 2025 13,170,715        
Balance at Dec. 31, 2024 $ 804 67,279,033 (60,410,041) 9,063 $ 6,878,859
Balance (in Shares) at Dec. 31, 2024 8,042,747       8,042,747
Common stock issued for cash, net (in Shares)         96,641
Net loss         $ (5,675,312)
Balance at Jun. 30, 2025 $ 1,323 75,815,158 (66,085,353) 12,044 $ 9,743,172
Balance (in Shares) at Jun. 30, 2025 13,234,027       13,234,027
Balance at Mar. 31, 2025 $ 1,317 75,415,913 (63,885,877) 8,566 $ 11,539,919
Balance (in Shares) at Mar. 31, 2025 13,170,715        
Issuance of warrants for professional fees 333,150 333,150
Common stock issued for cash, net $ 6 66,095 $ 66,101
Common stock issued for cash, net (in Shares) 63,312       88,312
Cumulative translation adjustment 3,478 $ 3,478
Net loss (2,199,476) (2,199,476)
Balance at Jun. 30, 2025 $ 1,323 $ 75,815,158 $ (66,085,353) $ 12,044 $ 9,743,172
Balance (in Shares) at Jun. 30, 2025 13,234,027       13,234,027
[1] Represents the aggregate fair value of 2,500,000 shares of common stock, which includes 955,000 shares that have been issued and 1,545,000 shares held in abeyance as of June 30, 2024.See Note 5 – Stockholders’ Equity – Warrants for additional information.